ASCO 2020: Donafenib Compares Well to Sorafenib in Open-Label Trial for Advanced Hepatocellular Carcinoma
Donafenib was associated with a better overall survival rate and tolerability profile
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.